Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia

Novel drug helps optimize HFrEF therapy
27 Apr 2022
bởiAudrey Abella
In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.